Stockreport

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (=90%), Approved in Japan to Treat ATTR-CM

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase [Read more]